Clinical benefits of evolocumab appear less than hoped - Authors' reply

Affiliations

¹ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: rgiugliano@bwh.harvard.edu.
² Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
³ International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.
⁴ Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.
⁵ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Free article

Comment

Robert P Giugliano et al. Lancet. 2018.

Free article

. 2018 Mar 10;391(10124):934-935.

doi: 10.1016/S0140-6736(18)30529-4.

¹ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: rgiugliano@bwh.harvard.edu.
² Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
³ International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, UK.
⁴ Oslo University Hospital, Ullevål and Medical Faculty, University of Oslo, Oslo, Norway.
⁵ TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

No abstract available

Comment on

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304224 Clinical Trial.